Key result
Antiplatelet agents target various pathways to reduce ischemic events, with ongoing developments focusing on new ADP, thrombin, and thromboxane receptor antagonists to improve clinical outcomes.
Design
Review
Authors
Loading...
May guide antiplatelet selection in ischemic disease; leaves open the net benefit of emerging ADP, thrombin, and thromboxane antagonists.
This review summarizes established and emerging antiplatelet agents, highlighting new ADP receptor antagonists and novel targets for cardiovascular and cerebrovascular disease management.
Steigerwald et al. (2009) conducted a review in cardiovascular or cerebrovascular ischemic diseases. Antiplatelet agents was evaluated. Antiplatelet agents target various pathways to reduce ischemic events, with ongoing developments focusing on new ADP, thrombin, and thromboxane receptor antagonists to improve clinical outcomes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: